In contrast, there was no difference in distant cancer recurrence between patients with or without CTA-expression in TFL in the discovery cohort, while in the validation cohort the difference in distant cancer recurrence between patients with and without CTA-expression in TFL was small and borderline significant (p = 0.046) (Figure S6). Here, ZC3H12D is linked to cancer.